EAGAN, Minn.--(BUSINESS WIRE)--Biothera, the immune health company, has initiated a Phase I/II clinical trial to evaluate the effects of its lead drug compound Imprime PGG™ in combination with G-CSF for mobilization of bone marrow stem cells into the peripheral blood in normal human subjects.
